• Enliven Therapeutics posted a net loss of USD 23.6 million, narrowing from USD 28.5 million a year earlier, while R&D expense fell to USD 20.7 million from USD 24.9 million.
• Operating loss narrowed to USD 27.8 million from USD 31.7 million, while G&A expense rose to USD 7.1 million from USD 6.8 million.
• Cash, cash equivalents and marketable securities totaled USD 452.4 million at March 31, down from USD 462.6 million at end-2025, providing runway into first half of 2029.
• Phase 1 data update for ELVN-001 expected mid-2026, with Phase 3 ENABLE-2 initiation expected in second half of 2026 alongside FDA interactions on dose selection and trial design.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605071605PR_NEWS_USPR_____LA53046) on May 07, 2026, and is solely responsible for the information contained therein.